Altimmune (ALT)
(Delayed Data from NSDQ)
$3.60 USD
-0.07 (-1.91%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $3.60 0.00 (0.00%) 7:22 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALT 3.60 -0.07(-1.91%)
Will ALT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALT
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
Will Healthy Y/Y Revenue Growth Boost Keysight's Q2 Earnings?
ALT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Doximity Q4 Earnings Likely to Reflect Strong Product Momentum
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86%
Altimmune Stock Up More Than 25% in a Month: Here's Why
Other News for ALT
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August ...
Altimmune: Potential Tough Road Ahead Amid Fierce Competition (Rating Downgrade)
Largest borrow rate increases among liquid names
Altimmune (ALT) Target Price Lowered by JMP Securities | ALT Stock News
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session